Literature DB >> 32715366

Blood thiamine pyrophosphate concentration and its correlation with the stage of diabetic retinopathy.

Emine Cinici1, Nilay Dilekmen2, Onur Senol3, Eren Arpalı4, Ozkan Cinici5, Serdar Tanas6.   

Abstract

PURPOSE: To assess the possible relationship between blood thiamine pyrophosphate (TPP) concentration and stage of diabetic retinopathy (DR).
METHODS: This comparative cross-sectional study included 80 patients with type 2 diabetes mellitus (T2DM) and 20 age- and gender-matched healthy controls. Diabetic patients were subclassified into four groups each consisting of 20 subjects: no DR, mild-moderate non-proliferative DR (mild-moderate NPDR), severe NPDR, and proliferative DR (PDR). Blood TPP concentration was assessed with high-performance liquid chromatography (HPLC) assay and was correlated with the stage of DR.
RESULTS: Mean blood TPP concentration was 80.2 ± 14.8 nmol/L in control group. It was, respectively, 69.85 ± 18.1, 64.95 ± 13.4, 61.9 ± 13.4 and 60.75 ± 14.3 nmol/L in no DR, mild-moderate NPDR, severe NPDR and PDR groups. For mild-moderate NPDR, severe NPDR and PDR groups, TPP concentrations were significantly lower compared with controls (p: 0.014, 0.002, 0.001, respectively). Mean TPP concentration for NPDR patients was higher than for PDR patients, but the difference was not significant (p: 0.478). ANOVA revealed a significant difference between TPP concentrations of groups (p: 0.001). Mean TPP concentration decreased with the stage of DR, and number of patients with thiamine deficiency increased gradually with the stage of DR. A negative correlation was found between the TPP level and occurrence of DR (p: 0.000).
CONCLUSION: The results suggest that lower blood TPP concentrations were associated with higher risk of DR. Thiamine might play an important role in the pathophysiology and progression of DR. Thiamine and its derivatives might represent an approach to the prevention and/or treatment of early DR.

Entities:  

Keywords:  Blood thiamine pyrophosphate concentration; Diabetic retinopathy; Thiamine; Thiamine pyrophosphate

Mesh:

Substances:

Year:  2020        PMID: 32715366     DOI: 10.1007/s10792-020-01513-2

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage.

Authors:  T Nishikawa; D Edelstein; X L Du; S Yamagishi; T Matsumura; Y Kaneda; M A Yorek; D Beebe; P J Oates; H P Hammes; I Giardino; M Brownlee
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Emerging role of thiamine therapy for prevention and treatment of early-stage diabetic nephropathy.

Authors:  N Rabbani; P J Thornalley
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

3.  Thiamine reverses hyperglycemia-induced dysfunction in cultured endothelial cells.

Authors:  E Ascher; P V Gade; A Hingorani; S Puthukkeril; S Kallakuri; M Scheinman; T Jacob
Journal:  Surgery       Date:  2001-11       Impact factor: 3.982

4.  Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy.

Authors:  M Yokoi; S-I Yamagishi; M Takeuchi; K Ohgami; T Okamoto; W Saito; M Muramatsu; T Imaizumi; S Ohno
Journal:  Br J Ophthalmol       Date:  2005-06       Impact factor: 4.638

5.  Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy.

Authors:  Hans-Peter Hammes; Xueliang Du; Diane Edelstein; Tetsuya Taguchi; Takeshi Matsumura; Qida Ju; Jihong Lin; Angelika Bierhaus; Peter Nawroth; Dieter Hannak; Michael Neumaier; Regine Bergfeld; Ida Giardino; Michael Brownlee
Journal:  Nat Med       Date:  2003-02-18       Impact factor: 53.440

6.  Serum and tear levels of nerve growth factor in diabetic retinopathy patients.

Authors:  Kyoung Soo Park; Sung Soo Kim; Jae Chan Kim; Hyeon Chang Kim; Yong Sun Im; Chul Woo Ahn; Hyung Keun Lee
Journal:  Am J Ophthalmol       Date:  2008-03       Impact factor: 5.258

Review 7.  Effects of thiamine and benfotiamine on intracellular glucose metabolism and relevance in the prevention of diabetic complications.

Authors:  Elena Beltramo; Elena Berrone; Sonia Tarallo; Massimo Porta
Journal:  Acta Diabetol       Date:  2008-06-26       Impact factor: 4.280

Review 8.  Current approaches and perspectives in the medical treatment of diabetic retinopathy.

Authors:  Massimo Porta; Attilio Allione
Journal:  Pharmacol Ther       Date:  2004-08       Impact factor: 12.310

9.  The impact of thiamine treatment in the diabetes mellitus.

Authors:  Khanh Vinh Quoc Luong; Lan Thi Hoang Nguyen
Journal:  J Clin Med Res       Date:  2012-05-15

Review 10.  The role of angiogenesis in the development of proliferative diabetic retinopathy: impact of intravitreal anti-VEGF treatment.

Authors:  Gemma Tremolada; Claudia Del Turco; Rosangela Lattanzio; Silvia Maestroni; Anna Maestroni; Francesco Bandello; Gianpaolo Zerbini
Journal:  Exp Diabetes Res       Date:  2012-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.